In this current study, we hypothesized that IG of CF can treat T2DM combined with NAFLD by improving T2DM through activating the PI3K-AKT pathway on one hand and ameliorating NAFLD via inhibiting the NF-κB pathway on the other. This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatotic liver disease.